TAFALGIE THERAPEUTICS Announces First Dose Escalation Data From TAFAFIRST, a Phase 1 Clinical Trial Evaluating TT5, a first-in-class Non-Opioid Treatment For Pain Marseille (France), July 10, 2025 – TAFALGIE THERAPEUTICS, a biopharmaceutical company specializing in the research and development of novel non-opioid pain treatments, today announces the first dose-escalation data from TAFAFIRST, a Phase 1 […]
Lire la suiteTafalgie Therapeutics selected as a finalist for the regional EY Entrepreneur of the Year 2024 award On Thursday, September 19, 2024, Tafalgie Therapeutics was selected as a finalist for the EY Entrepreneur of the Year 2024 award in the Start-up category for the South-East region of France. This recognition came during the regional finals of […]
Lire la suiteFrance Inter’s Thierry Lhermitte visits Aziz Moqrich’s laboratory at IBDM France Inter’s Thierry Lhermitte has visited Aziz Moqrich’s laboratory at IBDM. Discover the podcast interview here: Discovered
Lire la suite